Serum miRNA profile as a potential tool for non-invasive gastric cancer diagnosis in Mexican patients

4065 Background: High mortality from gastric cancer is related to the late manifestation of its symptoms. A blood-based non-invasive biomarker with the ability to detect all stages of gastric cancer could significantly improve patient outcomes. We aimed to develop a novel serum miRNA assay for diagnosis of gastric cancer. Methods: We conducted a multi-center study involving 892 gastric cancer and control subjects from Singapore and Korea to develop a multi-target miRNA assay. Using RT-qPCR, we quantified the expressions of 578 serum miRNAs and constructed a 12-miR biomarker panel through multi-variant data analysis. The results were generated with the use of a logistic-regression algorithm, with the value of 40 or more considered to be positive. We subsequently validated this multi-miR assay in a large prospective cohort involving 4566 subjects and compared its performance with traditional markers such as H.Pylori and Pepsinogen. All participants underwent gastroscopy independent of the assay results. Results: Of the 4566 subjects that underwent gastroscopy and histopathological examination in the prospective cohort, 125 were diagnosed with gastric cancer. The 12-miR assay achieved an Area-Under-Curve (AUC) of 0.84, significantly outperforming (p-value < 0.01) that of H.Pylori (AUC of 0.64) and Pepsinogen (AUC of 0.62). The sensitivity of the miRNA assay in detecting early (stage 0-2) and late (stage 3-4) stage gastric cancer was 82.6% (95% CI, 68.6% to 92.2%) and 88.4% (95% CI, 78.4% to 94.9%) respectively at a specificity of 70.0% (95% CI, 67.8% to 71.9%). In comparison, H.Pylori showed a sensitivity of 80.4% at a specificity of 44.3% whereas the Pepsinogen showed sensitivity of 9.52% at a specificity of 95.3%. Using the miRNA assay as a pre-screening tool could potentially reduce number of endoscopy needed by 62% in detecting one case of gastric cancer. Conclusions: Our serum miRNA panel is a useful, non-invasive screening test for gastric cancer. It is cost-effective as it can reduce unnecessary diagnostic endoscopy.

Download Full-text

Non-invasive biomarkers for gastric cancer diagnosis: ready for prime time?

Minerva Biotecnologica ◽

10.23736/s1120-4826.18.02463-1 ◽

2019 ◽

Vol 31 (1) ◽

Cited By ~ 2

Author(s):

Davide G. Ribaldone ◽

Daniele Simondi ◽

Elisa Petrini ◽

Marco Astegiano ◽

Marilena Durazzo

Keyword(s):

Gastric Cancer ◽

Cancer Diagnosis ◽

Prime Time ◽

Non Invasive

Download Full-text

UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF EARLY GASTRIC CANCER

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2014.6.1 ◽

2015 ◽

pp. 5-14

Author(s):

Van Huy Tran ◽

Quang Trung Tran

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Early Diagnosis ◽

Cancer Diagnosis ◽

Good Prognosis ◽

Accurate Diagnosis ◽

White Light Endoscopy ◽

Key Factor ◽

Magnified Endoscopy ◽

Endoscopic Characteristics

The prognosis of gastric cancer depends principally upon an early diagnosis. An early and accurate diagnosis of gastric cancer needs some basic knowledges about the endoscopic characteristics of white light endoscopy, chromoendoscopy, magnified endoscopy, FICE and NBI…A strategy of screening is also a key factor for early diagnosis. The treatment of early gastric cancer by endoscopy techniques have showed more and more advantages. Beside of EMR, the technique of ESD is now applied more widely and lead to a very good prognosis and nearly a curative treatment for the patients with early gastric cancer. Key words: gastric cancer, early gastric cancer, diagnosis, endoscopy

Download Full-text

Faculty Opinions recommendation of Real-time Raman spectroscopy for in vivo, online gastric cancer diagnosis during clinical endoscopic examination.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725977676.793511969 ◽

2015 ◽

Author(s):

Matthew Banks

Keyword(s):

Gastric Cancer ◽

Raman Spectroscopy ◽

Real Time ◽

Cancer Diagnosis ◽

Endoscopic Examination

Download Full-text

Faculty Opinions recommendation of CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727438444.793530754 ◽

2017 ◽

Author(s):

Chao Cheng

Keyword(s):

Cancer Diagnosis ◽

Invasive Cancer ◽

Cell Free Dna ◽

Non Invasive ◽

Free Dna ◽

Tissue Of Origin

Download Full-text

Non-Invasive Dengue Diagnostics—The Use of Saliva and Urine for Different Stages of the Illness

Diagnostics ◽

10.3390/diagnostics11081345 ◽

2021 ◽

Vol 11 (8) ◽

pp. 1345

Author(s):

Mahathir Humaidi ◽

Wei Ping Tien ◽

Grace Yap ◽

Choon Rong Chua ◽

Lee Ching Ng

Keyword(s):

Clinical Symptoms ◽

Detection Algorithm ◽

Acute Stage ◽

Serum Samples ◽

Non Invasive ◽

Fever Onset ◽

Dengue Transmission ◽

Dengue Diagnostics ◽

Potential Tool

Dengue diagnosis is largely dependent on clinical symptoms and routinely confirmed with laboratory detection of dengue virus in patient serum samples collected via phlebotomy. This presents a challenge to patients not amenable to venipuncture. Non-invasive methods of dengue diagnosis have the potential to enhance the current dengue detection algorithm. In this study, samples from dengue infected patients were collected between January 2012 until September 2012 and September 2013 until December 2013 in two different setups. Panel A samples (blood, urine, and saliva) were collected daily when the 39 patients were hospitalised and during their follow-up visits while Panel B samples (saliva) were collected from 23 patients during the acute stage of dengue. Using DENV PCR on Panel A, from day 2 to day 4 post fever onset, serum showed the best overall positivity followed by saliva and urine (100%/82.1%/67.9%). From day 5 until day 10 post fever onset, serum and urine had similar positivity (67.4%/61.2%), followed by saliva (51.3%). Beyond day 10 post fever onset, DENV was undetectable in sera, but urine and saliva showed 56.8% and 28.6% positivity, respectively. DENV in urine was detectable up until 32 days post fever. Panel B results showed overall sensitivity of 32.4%/36% (RNA/NS1) for DENV detection in saliva. Our results suggest that the urine-based detection method is useful especially for late dengue detection, where DENV is undetected in sera but still detectable in urine. This provides a potential tool for the physician to pick up new cases in an area where there is ongoing dengue transmission and subsequently prompt for intensified vector control activities.

Download Full-text

Rapid and sensitive leukemia-derived exosome quantification via nicking endonuclease-assisted target recycling

Analytical Methods ◽

10.1039/d1ay00854d ◽

2021 ◽

Author(s):

meng yang zhou ◽

chao li ◽

bao long wang ◽

Lin Huang

Keyword(s):

Cancer Diagnosis ◽

Invasive Cancer ◽

Great Promise ◽

Current Analysis ◽

Target Recycling ◽

Nicking Endonuclease ◽

Non Invasive ◽

Analysis Process

Exosomes as fluid biomarkers hold great promise for non-invasive cancer diagnosis. However, a method with rapid and convenient for exosome detection is still challenging duo to the current analysis process...

Download Full-text

Comparison of 68Ga-FAPI-04 and 18F-FDG for the Detection of Primary Gastric Cancers and Metastasis

10.21203/rs.3.rs-326617/v1 ◽

2021 ◽

Author(s):

Donglang Jiang ◽

Xing Chen ◽

Zhiwen You ◽

Hao Wang ◽

Xiaoyun Zhang ◽

...

Keyword(s):

Gastric Cancer ◽

Cell Carcinoma ◽

Cancer Diagnosis ◽

Fdg Pet ◽

Standardized Uptake Value ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Gastric Cancers ◽

Signet Ring ◽

Ring Cell

Abstract Introduction Early and precise diagnosis and staging of gastric cancer are important for its treatment and management. However, the low sensitivity of 18F-fluorodeoxyglucose (18F-FDG) for gastric cancer diagnosis limits its application. Currently, the tracer 68Ga-FAPI, which targets fibroblast activation protein (FAP), is widely used to diagnose various cancers. However, the diagnostic value of 68Ga-FAPI in gastric cancer is still unclear. In this study, we aimed to investigate the potential advantage of 68Ga-FAPI-04 over 18F-FDG in the evaluation of gastric cancer.Methods: Thirty-eight patients with gastric cancer (31 with adenocarcinoma and 7 with signet ring cell carcinoma) were recruited for this study. All of the participants underwent 68Ga-FAPI-04 and 18F-FDG imaging by positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance (MR). The results were interpreted by two experienced nuclear medicine physicians, and the maximum standardized uptake value (SUVmax) was calculated.Results: For the detection of primary gastric cancer, the sensitivities of 68Ga-FAPI-04 PET and 18F-FDG PET were 100% (38/38) and 81.6% (31/38), respectively. Four cases of adenocarcinoma and three cases of signet ring cell carcinoma were missed by 18F-FDG PET. The SUVmax of 68Ga-FAPI-04 in tumors greater than 4 cm (11.0 ± 4.5) was higher than tumors less than 4 cm (4.5 ± 3.2) (P = 0.0015). The SUVmax of 68Ga-FAPI-04 was higher in T2-4 tumors (9.7 ± 4.4) than in T1 tumors (3.1 ± 1.5) (P = 0.0002). For the detection of metastatic lesions, the sensitivities of 68Ga-FAPI-04 PET and 18F-FDG PET in 10 patients with regional lymph node metastasis and distant metastasis were 6/10 and 5/10, respectively.Conclusion: Compared to 18F-FDG PET, 68Ga-FAPI-04 PET had superior potential in detecting primary gastric cancers and metastatic lymph nodes, 68Ga-FAPI-04 PET also had a better performance on small gastric cancer detection. 68Ga-FAPI-04 PET could provide better performance for gastric cancer diagnosis and staging.

Download Full-text